December 19, 2017 / 8:48 PM / 9 months ago

BRIEF-FDA Says Approved Exelixis' sNDA For Patients With Previously Untreated Advanced RCC

Dec 19 (Reuters) - FDA:

* FDA SAYS APPROVED EXELIXIS' SNDA FOR PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED RCC

* FDA SAYS GRANTED EXELIXIS' CURRENTLY APPROVED TREATMENT OPTION BROADENED LABEL THAT NOW INCLUDES ALL ELIGIBLE PATIENTS WITH ADVANCED RCC Source text (bit.ly/2BLPF5L) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below